179 related articles for article (PubMed ID: 27576612)
21. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
Kathpalia M; Mishra P; Bajpai R; Bhurani D; Agarwal N
Ann Hematol; 2022 Aug; 101(8):1655-1666. PubMed ID: 35727338
[TBL] [Abstract][Full Text] [Related]
23. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
Boddu PC; Senapati J; Ravandi-Kashani F; Jabbour EJ; Jain N; Ayres M; Chen Y; Keating MJ; Kantarjian HM; Gandhi V; Kadia TM
Cancer; 2023 Feb; 129(4):580-589. PubMed ID: 36448227
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
Gandhi V; Plunkett W; Weller S; Du M; Ayres M; Rodriguez CO; Ramakrishna P; Rosner GL; Hodge JP; O'Brien S; Keating MJ
J Clin Oncol; 2001 Apr; 19(8):2142-52. PubMed ID: 11304766
[TBL] [Abstract][Full Text] [Related]
25. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.
Reilly KM; Kisor DF
Onco Targets Ther; 2009 Feb; 2():219-28. PubMed ID: 20616909
[TBL] [Abstract][Full Text] [Related]
26. Nelarabine-associated reversible Guillain-Barré-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma.
Lalayanni C; Baldoumi E; Papayiannopoulos S; Tziola K; Saloum R; Anagnostopoulos A
Curr Probl Cancer; 2017; 41(2):138-143. PubMed ID: 28169005
[TBL] [Abstract][Full Text] [Related]
27. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
Karthik U; Motwani J
J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
[TBL] [Abstract][Full Text] [Related]
29. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Dunsmore KP; Devidas M; Linda SB; Borowitz MJ; Winick N; Hunger SP; Carroll WL; Camitta BM
J Clin Oncol; 2012 Aug; 30(22):2753-9. PubMed ID: 22734022
[TBL] [Abstract][Full Text] [Related]
30. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
[TBL] [Abstract][Full Text] [Related]
31. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
[TBL] [Abstract][Full Text] [Related]
32. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
DeAngelo DJ; Yu D; Johnson JL; Coutre SE; Stone RM; Stopeck AT; Gockerman JP; Mitchell BS; Appelbaum FR; Larson RA
Blood; 2007 Jun; 109(12):5136-42. PubMed ID: 17344466
[TBL] [Abstract][Full Text] [Related]
33. Nelarabine: a new purine analog in the treatment of hematologic malignancies.
Curbo S; Karlsson A
Rev Recent Clin Trials; 2006 Sep; 1(3):185-92. PubMed ID: 18473971
[TBL] [Abstract][Full Text] [Related]
34. Clofarabine and nelarabine: two new purine nucleoside analogs.
Gandhi V; Plunkett W
Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
[TBL] [Abstract][Full Text] [Related]
35. Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression.
Cialfi S; Palermo R; Manca S; Checquolo S; Bellavia D; Pelullo M; Quaranta R; Dominici C; Gulino A; Screpanti I; Talora C
Leukemia; 2013 Feb; 27(2):485-8. PubMed ID: 22846929
[No Abstract] [Full Text] [Related]
36. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Massie T; Sridhara R; McGuinn WD; Abraham S; Booth BP; Goheer MA; Morse D; Chen XH; Chidambaram N; Kenna L; Gobburu JV; Justice R; Pazdur R
Clin Cancer Res; 2006 Sep; 12(18):5329-35. PubMed ID: 17000665
[TBL] [Abstract][Full Text] [Related]
37. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
Candoni A; Lazzarotto D; Petruzzellis G
Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
[TBL] [Abstract][Full Text] [Related]
38. Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity.
Kanayama T; Imamura T; Nakagawa N; Osone S; Hosoi H
Pediatr Int; 2017 Jul; 59(7):843-845. PubMed ID: 28745456
[No Abstract] [Full Text] [Related]
39. Changes in intracellular activation-related gene expression and induction of Akt contribute to acquired resistance toward nelarabine in CCRF-CEM cell line.
Rindiarti A; Okamoto Y; Nakagawa S; Hirose J; Kodama Y; Nishikawa T; Kawano Y
Leuk Lymphoma; 2022 Feb; 63(2):404-415. PubMed ID: 35080473
[TBL] [Abstract][Full Text] [Related]
40. Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Cooper TM
Ther Clin Risk Manag; 2007 Dec; 3(6):1135-41. PubMed ID: 18516261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
